Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Kenny-Caffey syndrome, Type 1 1 Breast Neoplasms 1

Interventions

Cisplatin 3202 Cyclophosphamide 3195 Carboplatin 2977 Radiotherapy 2790 Paclitaxel 2718 Gemcitabine 2572 pembrolizumab 2384 Bevacizumab 2209 Docetaxel 2199 Fluorouracil 1851 Capecitabine 1831 Oxaliplatin 1742 Dexamethasone 1605 Nivolumab 1581 Doxorubicin 1501 Rituximab 1488 Magnetic Resonance Spectroscopy 1387 Etoposide 1346 Irinotecan 1248 Leucovorin 1226 Drug Therapy 1205 Cytarabine 1130 Pemetrexed 1076 fludarabine 1063 Specimen Handling 1016 Vincristine 964 Cetuximab 945 Trastuzumab 944 Prednisone 941 Lenalidomide 937

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Vernalization × Clear all

NCT02789332 2020-03-17

GeparOla

GBG Forschungs GmbH

Phase 2 Completed

Kenny-Caffey syndrome, Type 1, Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡